目前或过去高血症患者心力衰竭药物优化的帕提罗默: DIAMOND 亚分析
Andrew J S Coats1, Stefan D Anker2, Lars H Lund3
1Heart Research Institute, Sydney, New South Wales, Australia.
JACC. Heart failure
|September 28, 2024
概括
帕蒂罗默有助于管理心力衰竭患者的高卡利米亚,使氨酸-氨酸-阿尔多斯特系统抑制剂 (RAASis) 的最佳使用成为可能. 它在降低水平和维持矿物质皮质类受体抗剂 (MRA) 目标剂量方面被证明是有效的,特别是在当前高血症患者中.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 降低射出分数 (HFrEF) 的心力衰竭治疗往往受到高胆血症的限制,导致对氨酸-氨酸-阿尔多斯特系统抑制剂 (RAASis) 的低最佳使用.
- 结合剂提供了减轻高血症的潜在解决方案,从而改善RAASi治疗在HFrEF患者的坚持和疗效.
研究的目的:
- 评估帕蒂罗默在治疗HFrEF患者高卡莱米亚的疗效.
- 评估patiomer对达到RAASis的目标剂量的影响,包括矿物质皮质醇受体对抗剂 (MRAs),在患有当前或过去高血症的患者中.
主要方法:
- 对参与HFrEF和当前或过去高血症患者的第3期DIAMOND试验的预规定的分析.
- 患者经历了一个运行阶段以优化RAASis与patieromer,然后随机选择继续patieromer或以双盲方式切换到安慰剂.
- 在整个研究过程中,血清 (sK+) 水平和MRA治疗的坚持得到了监测.
主要成果:
- 与安慰剂相比,Patiromer在当前和过去的高血症子组中显著降低了血清水平.
- 帕蒂罗默在当前高胆固醇血症患者的目标剂量中维持MRA方面比过去高胆固醇血症患者更有效.
- 患者组和安慰剂组之间以及超血症亚组之间,不良事件是可比的.
结论:
- 帕蒂罗默促进了HFrEF患有高血症的患者达到和维持目标RAASi剂量.
- 帕蒂罗默的使用似乎对患有当前高胆血症的患者特别有益,有助于控制和优化MRA剂量.
- 帕蒂罗默是一种安全有效的选择,用于管理HFrEF患者的高卡利米亚,从而改善了指导方针导向医学治疗的利用率.
相关概念视频
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:26Heart Failure Drugs: Inotropic Agents
535
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
535
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
469
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
469